Michael Davis becomes Cyanotech chairman

Hawaiian microalgae technology company looks forward to continuing support of its major shareholder

Michael Davis has been elected as chairman of Hawaii-based Cyanotech Corporation. He replaces Gregg Robertson, who resigned in late 2010.

Davis was vice-chairman of the board and has been a director of Cyanotech since March 2003.

‘Michael has been a key influence in helping Cyanotech sharpen its business model and market focus in recent years,’ said Brent Bailey, president and ceo. ‘We look forward to his continuing support and leadership as chairman of the board.’

Cyanotech Corporation, a microalgae technology specialist, produces BioAstin Natural Astaxanthin and Hawaiian Spirulina Pacifica, which are natural, functional nutrients.

You may also like

Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Olon: celebrating 10 years of daptomycin and doubled production capacity

Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Ingredients

Rousselot announces access to pure gelatins through BIO INX

Research and technical grade gelatins are now available for online purchase in Canada, Europe, South Korea and the US
Manufacturing

Exploring TiO2-free hard capsules

The quest for TiO2 alternatives underscores the unwavering commitment of the pharmaceutical industry to deliver safe and effective medicines to patients worldwide
Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Subscribe now